IP Library Granted Patent US 12,460,254
Granted Patent B2
US 12,460,254 · App. 17/266,060 · Granted Nov 4, 2025

Compositions, methods and kits for detecting

Inventors: Brett W. Kirkconnell (San Diego, CA); Barbara S. Weinbaum (La Jolla, CA); Damon K. Getman (Poway, CA); Alice Jiang (San Diego, CA)
Assignee: Gen-Probe Incorporated
C12Q1/6844C12Q1/689
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,460,254
App. No.
17/266,060
Granted
Nov 4, 2025
Kind
B2
Abstract

The present disclosure relates to oligonucleotides useful for determining the presence of Mycoplasma genitalium in a test sample. The oligonucleotides of the present disclosure may be incorporated into hybridization assay probes, capture probes and amplification primers, and used in various combinations thereof.

Claims (11)

1 . An oligonucleotide probe for detecting nucleic acids of Mycoplasma genitalium , consisting of:

a target-hybridizing sequence of bases consisting of SEQ ID NO:2 in which thymines may optionally be substituted with uracils, with a non-nucleotide linker positioned between bases 6 and 7 of SEQ ID NO:2; and

a detectable label attached to the non-nucleotide linker.

2 . The oligonucleotide probe of claim 1 , wherein the detectable label comprises a chemiluminescent label.

3 . The oligonucleotide probe of claim 2 , wherein the chemiluminescent label comprises an acridinium ester.

4 . An oligonucleotide probe for detecting nucleic acids of Mycoplasma genitalium , consisting of:

a target-hybridizing sequence of bases consisting of the base sequence of SEQ ID NO:3 in which thymines may optionally be substituted with uracils, with a non-nucleotide linker between base positions 6 and 7 of SEQ ID NO:3; and

a detectable label attached to the non-nucleotide linker.

5 . The oligonucleotide probe of claim 4 , wherein the detectable label comprises a chemiluminescent label.

6 . The oligonucleotide probe of claim 5 , wherein the chemiluminescent label comprises an acridinium ester.

7 . The oligonucleotide probe of claim 4 , wherein the base sequence of the target-hybridizing sequence is SEQ ID NO: 3 with the non-nucleotide linker between base positions 6 and 7.

Assignments (3)
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2025
From: KIRKCONNELL, BRETT; GETMAN, DAMON K.; WEINBAUM, BARBARA S.; JIANG, ALICE
To: GEN-PROBE INCORPORATED
Reel/Frame 072110/0774 →
SECURITY INTEREST Recorded Oct 12, 2021
From: HOLOGIC, INC.; FAXITRON BIOPTICS, LLC; BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 057787/0526 →
Continuity (2)
Provisional Application 62716241 · Aug 8, 2018
Related Publication 20210310059A1 · Oct 7, 2021
References Cited (15)
US 5969122A · Hammond et al. · 1999 [cited by applicant]
US 6031091A · Arnold, Jr. · 2000 [cited by examiner]
US 7345155B2 · Cunningham et al. · 2008 [cited by applicant]
US 20030194723A1 · Cunningham · 2003 [cited by examiner]
US 20170039316A1 · Fofanov · 2017 [cited by examiner]
JP 2002281980A · 2002 [cited by examiner]
WO WO2009039549A2 · 2009 [cited by examiner]
WO 2017202895A1 · 2017 [cited by applicant]
Machine Translation of WO-2009039549-A2. Obtained Dec. 11, 2023. (Year: 2009). [cited by examiner]
GenBank Accession No. AB069813 (Year: 2002). [cited by examiner]
Machine Translation of JP-2002281980-A. (Year: 2002). [cited by examiner]
Jensen et al. “Detection of [cited by applicant]
Jensen et al. “Azithromycin Treatment Failure in [cited by applicant]
PCT, International Search Report and Written Opinion for Application No. PCT/US2019/045520, mailed Oct. 11, 2019, 16 pages. [cited by applicant]
EP, Office Action for European Application No. 19759144.9, dated Mar. 12, 2024, 9 pages. [cited by applicant]